Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Aarnoutse

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Trials|August 15, 2023
The effect of a customised digital adherence tool on HIV treatment outcomes in young people living with HIV (YPLHIV) in Blantyre, Malawi: a protocol for a randomised controlled trialTakondwa Charles Msosa, Iraseni Swai, Marion Sumari-de Boer, et al.
Trials|February 15, 2020
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)Ruth Nabisere, Joseph Musaazi, Paolo Denti, et al.
International Journal of Antimicrobial Agents|February 24, 2015
Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitisLindsey Te Brake, Sofiati Dian, Ahmad Rizal Ganiem, et al.
Chest|December 1, 2023
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized TrialSanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 10, 2024
The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-AnalysisTakondwa Charles Msosa, Iraseni Swai, Rob Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2025
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TBCaryn M Upton, Jose M Calderin, Andreas H Diacon, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 17, 2026
Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicityCynthia van Arkel, Ralf Stemkens, Cécile Magis-Escurra, et al.
International Journal of Antimicrobial Agents|May 9, 2015
SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis modelGerjo J de Knegt, Irma A J M Bakker-Woudenberg, Dick van Soolingen, et al.
AIDS (London, England)|June 24, 2003
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsDavid Burger, Patricia Hugen, Peter Reiss, et al.
Archives of Public Health = Archives Belges De Sante Publique|May 7, 2025
Engaging community pharmacy in tuberculosis case detection (ENHANCE): a study protocol for an implementation study in IndonesiaIvan Surya Pradipta, Carla Florencia, Cut Ainul Mardhiyyah, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Trials|August 15, 2023
The effect of a customised digital adherence tool on HIV treatment outcomes in young people living with HIV (YPLHIV) in Blantyre, Malawi: a protocol for a randomised controlled trialTakondwa Charles Msosa, Iraseni Swai, Marion Sumari-de Boer, et al.
Trials|February 15, 2020
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)Ruth Nabisere, Joseph Musaazi, Paolo Denti, et al.
International Journal of Antimicrobial Agents|February 24, 2015
Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitisLindsey Te Brake, Sofiati Dian, Ahmad Rizal Ganiem, et al.
Chest|December 1, 2023
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized TrialSanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 10, 2024
The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-AnalysisTakondwa Charles Msosa, Iraseni Swai, Rob Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2025
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TBCaryn M Upton, Jose M Calderin, Andreas H Diacon, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 17, 2026
Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicityCynthia van Arkel, Ralf Stemkens, Cécile Magis-Escurra, et al.
International Journal of Antimicrobial Agents|May 9, 2015
SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis modelGerjo J de Knegt, Irma A J M Bakker-Woudenberg, Dick van Soolingen, et al.
AIDS (London, England)|June 24, 2003
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsDavid Burger, Patricia Hugen, Peter Reiss, et al.
Archives of Public Health = Archives Belges De Sante Publique|May 7, 2025
Engaging community pharmacy in tuberculosis case detection (ENHANCE): a study protocol for an implementation study in IndonesiaIvan Surya Pradipta, Carla Florencia, Cut Ainul Mardhiyyah, et al.
Pageof 7